|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/28/17 Anika Therapeutics, Inc. 10-Q 6/30/17 62:2.7M Globenewswire Inc./FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 218K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
11: R1 Document And Entity Information HTML 45K
12: R2 Condensed Consolidated Balance Sheets (Current HTML 92K
Period Unaudited)
13: R3 Condensed Consolidated Balance Sheets (Current HTML 38K
Period Unaudited) (Parentheticals)
14: R4 Condensed Consolidated Statements of Operations HTML 75K
and Comprehensive Income (Unaudited)
15: R5 Condensed Consolidated Statements of Cash Flows HTML 96K
(Unaudited)
16: R6 Note 1 - Nature of Business HTML 23K
17: R7 Note 2 - Basis of Presentation HTML 27K
18: R8 Note 3 - Recent Accounting Pronouncements HTML 36K
19: R9 Note 4 - Investments HTML 23K
20: R10 Note 5 - Fair Value Measurements HTML 45K
21: R11 Note 6 - Equity Incentive Plan HTML 46K
22: R12 Note 7 - Earnings Per Share ("Eps") HTML 35K
23: R13 Note 8 - Inventories HTML 25K
24: R14 Note 9 - Intangible Assets HTML 39K
25: R15 Note 10 - Goodwill HTML 25K
26: R16 Note 11 - Accrued Expenses HTML 28K
27: R17 Note 12 - Commitments and Contingencies HTML 24K
28: R18 Note 13 - Leases HTML 25K
29: R19 Note 14 - Income Taxes HTML 29K
30: R20 Note 15 - Depuy Synthes Mitek Sports Medicine HTML 22K
Monovisc Agreement
31: R21 Note 16 - Segment and Geographic Information HTML 50K
32: R22 Note 5 - Fair Value Measurements (Tables) HTML 41K
33: R23 Note 6 - Equity Incentive Plan (Tables) HTML 37K
34: R24 Note 7 - Earnings Per Share ("Eps") (Tables) HTML 28K
35: R25 Note 8 - Inventories (Tables) HTML 26K
36: R26 Note 9 - Intangible Assets (Tables) HTML 34K
37: R27 Note 10 - Goodwill (Tables) HTML 24K
38: R28 Note 11 - Accrued Expenses (Tables) HTML 27K
39: R29 Note 16 - Segment and Geographic Information HTML 51K
(Tables)
40: R30 Note 3 - Recent Accounting Pronouncements (Details HTML 21K
Textual)
41: R31 Note 4 - Investments (Details Textual) HTML 23K
42: R32 Note 5 - Fair Value Measurements - Fair Value of HTML 37K
Financial Instruments (Details)
43: R33 Note 6 - Equity Incentive Plan (Details Textual) HTML 42K
44: R34 Note 6 - Equity Incentive Plan - Assumptions Used HTML 31K
to Estimate Fair Value of Stock Options and Stock
Appreciation Rights Awards (Details)
45: R35 Note 6 - Equity Incentive Plan - Total Stock-based HTML 26K
Compensation Expense (Details)
46: R36 Note 7 - Earnings Per Share ("Eps") (Details HTML 42K
Textual)
47: R37 Note 7 - Earnings Per Share ("EPS") - Basic and HTML 27K
Diluted Earnings Per Share (Details)
48: R38 Note 8 - Inventories - Inventories (Details) HTML 28K
49: R39 Note 9 - Intangible Assets (Details Textual) HTML 20K
50: R40 Note 9 - Intangible Assets - Intangible Assets HTML 42K
(Details)
51: R41 Note 10 - Goodwill - Changes in the Carrying Value HTML 22K
of Goodwill (Details)
52: R42 Note 11 - Accrued Expenses - Accrued Expenses HTML 37K
(Details)
53: R43 Note 12 - Commitments and Contingencies (Details HTML 20K
Textual)
54: R44 Note 13 - Leases (Details Textual) HTML 37K
55: R45 Note 14 - Income Taxes (Details Textual) HTML 33K
56: R46 Note 15 - Depuy Synthes Mitek Sports Medicine HTML 24K
Monovisc Agreement (Details Textual)
57: R47 Note 16 - Segment and Geographic Information HTML 18K
(Details Textual)
58: R48 Note 16 - Segment and Geographic Information - HTML 27K
Product Revenue by Product Group (Details)
59: R49 Note 16 - Segment and Geographic Information - HTML 28K
Total Revenue by Geographic Location (Details)
61: XML IDEA XML File -- Filing Summary XML 108K
60: EXCEL IDEA Workbook of Financial Reports XLSX 46K
5: EX-101.INS XBRL Instance -- anik-20170630 XML 758K
7: EX-101.CAL XBRL Calculations -- anik-20170630_cal XML 102K
8: EX-101.DEF XBRL Definitions -- anik-20170630_def XML 722K
9: EX-101.LAB XBRL Labels -- anik-20170630_lab XML 564K
10: EX-101.PRE XBRL Presentations -- anik-20170630_pre XML 744K
6: EX-101.SCH XBRL Schema -- anik-20170630 XSD 126K
62: ZIP XBRL Zipped Folder -- 0001171843-17-004447-xbrl Zip 80K
Exhibit 32.1
Section 906 Certification
The undersigned officers of Anika Therapeutics, Inc. (the “Company”) hereby certify to their knowledge and in their respective capacities that the Company’s quarterly report on Form 10-Q to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: July 28, 2017 | /s/ CHARLES H. SHERWOOD |
| Charles H. Sherwood, Ph.D. | |
| Chief Executive Officer | |
| Principal Executive Officer | |
|
| |
| Date: July 28, 2017 | /s/ SYLVIA CHEUNG |
| Sylvia Cheung | |
| Chief Financial Officer | |
| Principal Financial Officer |
This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing, under the Securities Act of 1933, as amended, or the Exchange Act.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 7/28/17 | None on these Dates | ||
| For Period end: | 6/30/17 | |||
| List all Filings | ||||